An abbreviated approval path for follow-on antibodies within a validated class
Once a class of antibody such as PD-1 blockers is proven, later copies could be approved on smaller trials showing equivalence, forcing price competition and freeing patients and money for genuinely new drugs.
For mechanistic classes with multiple approved agents and well-understood pharmacology (anti-PD-1, anti-CD20, anti-HER2), regulators create a pathway between biosimilar and full novel approval: approval based on pharmacodynamic equivalence and a single non-inferiority efficacy trial against an approved class member, with pricing expected to follow biosimilar dynamics. This ends the wasteful situation in which each of a dozen PD-1 antibodies runs its own placebo- or chemotherapy-controlled phase 3 in populations already known to benefit, while giving payers real competition within class. Capital that cannot earn novel-drug returns on copies moves elsewhere.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.